A CRISPR-edited wheat has cut acrylamide in biscuits by 93 percent.
That number comes from two years of field trials on wheat engineered to silence the genes that produce free asparagine, the amino acid that converts into a probable carcinogen when heated above 120 degrees Celsius. The biscuit test was the most extreme proof point. Bread made from the same genetic line showed acrylamide below detection thresholds. After four minutes of toasting, levels held at 8 percent of the control.
The factory didn't change. The chemistry did.
The Gate Swings Open
On July 9, 2026, the UK government confirmed that a low-asparagine wheat meets the criteria of a precision-bred organism under the Genetic Technology (Precision Breeding) Act 2023 and its 2025 regulations. The technical lead is Professor Nigel Halford, a plant scientist at Rothamsted Research who has driven the project from lab bench to field. Seed World reported the milestone, quoting Halford: "Receiving this marketing notice is an important milestone, not only for this wheat but for the UK's new precision breeding framework."
The wheat that received the regulatory green light carries a knockout of the asparagine synthetase-2 gene, TaASN2. In field trials spanning 2021-2022 and published in the Plant Biotechnology Journal, this line reduced free asparagine by 59 percent across two years with no yield penalty. In baking tests, acrylamide in bread made from this line was 14 percent of the control. In biscuits, the reduction was 86 percent.
A second, more aggressive edit—a combined TaASN1/2 knockout—hit the headline 93 percent biscuit reduction and pushed bread acrylamide below detection levels. That line has not yet received precision-bred status. The TaASN2 line has. The distinction matters: the regulatory milestone belongs to the single-gene edit, and that is the wheat now moving toward commercial fields.
The Act draws a hard line between transgenic GMOs and genome-edited crops that could have arisen through traditional breeding. By classifying this wheat as the latter, it clears a path to real processing plants. The next step is Food Standards Agency approval, which would unlock the Defra-funded PROBITY project, running from March 2025 to September 2027, designed to bulk up seed on selected farms and run it through actual food manufacturing lines.
What Baking Creates
Acrylamide forms when free asparagine meets heat. The reaction is a chemical inevitability in baked, fried, roasted, and toasted wheat products. The International Agency for Research on Cancer classifies it as a Group 2A carcinogen—probably carcinogenic to humans. The EU introduced benchmark regulations in 2017, and food manufacturers have been wrestling with compliance ever since.
Their options are expensive and inconsistent. They can add the enzyme asparaginase to convert asparagine before baking—a recurring cost that introduces process variability. They can adjust baking temperatures and times, risking the texture and color consumers expect. They can reformulate recipes, which means reformulating brand identity. None of these solve the root problem. They manage it, at a cost, batch by batch.
The CRISPR approach solves it at the seed. Researchers used CRISPR/Cas9 to target TaASN2. The 2021-2022 field trials, confirmed as Europe's first field release of genome-edited wheat, were conducted on a 1500-square-metre plot. The yield data is the detail that will determine adoption: edited lines held steady while TILLING mutant lines, which achieved a more modest asparagine reduction, took a yield hit. Farmers will not plant a crop that penalizes output. The CRISPR lines don't.
The Scramble
The consensus frames this as a consumer health win. The harder read: this is a supply chain play. The real value is not reducing cancer risk for toast eaters. It is eliminating the costly, inconsistent post-processing steps that food manufacturers currently use to comply with acrylamide regulations. The wheat itself becomes the compliance tool.
Here is the chain.
First, the seed scales. The PROBITY project will bulk up winter wheat cultivar Cadenza low-asparagine lines 23 and 59 through September 2027. The government notification confirms Innovate UK funding and a defined endpoint: enough seed for real-world food manufacturing trials. This is not a hypothetical. It is a scaling exercise with a deadline.
Second, a manufacturer commits. Within 12 to 24 months of seed availability, at least one major UK food manufacturer will publicly commit to sourcing low-asparagine wheat for a flagship product line. The logic is cold: it is cheaper than buying enzymes and safer than gambling with regulatory thresholds. A first-mover advantage in marketing a product with inherently lower acrylamide is substantial. When that commitment lands, it triggers a cascade. Seed companies race to multiply seed. Contract farmers pivot acreage to capture the premium.
Third, the EU faces a choice. The UK has opened a regulatory path that the EU has not matched. If European manufacturers cannot access low-asparagine wheat while UK competitors can, the acrylamide compliance gap becomes a trade competitiveness gap in biscuits, bread, and breakfast cereals. The pressure to align regulations will mount. The companies that lobby early will shape the outcome.
Fourth, the consumer objection evaporates. This wheat will not be sold as a "CRISPR food." It will be sold as wheat. The benefit is invisible to the consumer, who sees the same loaf on the shelf. The UK's precision breeding framework does not require a label for crops that could have been bred conventionally. The "frankenfood" objection has no purchase when the product is identical in appearance, taste, and texture, and the health benefit is a reduction in something the consumer never knew was there.
Fifth, the precedent locks in. If a CRISPR-edited commodity crop can clear regulatory hurdles and win commercial adoption by targeting a food safety trait, the pipeline opens. Low-gluten wheat. Low-acrylamide potatoes. Reduced-allergen peanuts. Each targets a hidden industrial or health problem at the genetic root. Each offers manufacturers a way to comply with regulations without changing their factories.
What would falsify this prediction? Simple. If the PROBITY project concludes in September 2027 and no manufacturer has signed a sourcing agreement within 12 months, the thesis is wrong. The enzyme suppliers win. The regulatory milestone becomes a footnote.
What to Do Now
Food manufacturers: start due diligence on low-asparagine wheat supply now. The PROBITY project has a defined endpoint, and the seed will exist. The first mover gets a regulatory and marketing advantage that competitors will have to chase.
Seed companies: accelerate multiplication of the TaASN2 lines. The trait is validated across two years of field trials with no yield penalty. The demand signal from food manufacturers will arrive, and the company with seed ready to deploy wins the contracts.
UK farmers: watch for contract opportunities emerging from the PROBITY project. A premium crop that requires no new equipment and carries a built-in buyer is a rare asset.
EU food companies: lobby your regulators now. If UK competitors can access low-asparagine wheat and you cannot, the acrylamide compliance gap becomes a trade gap.
The Seed, Not the Oven
The first CRISPR-edited wheat to clear the UK's precision breeding framework did not require a single change to how biscuits are baked. It required a change to the seed that goes into the ground.
The factory stays the same. The chemistry does not. And now the regulatory home exists to put it in the field.
